Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease. Nat Rev Nephrol. 2019;15:346–66.
Article PubMed PubMed Central Google Scholar
Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540–55.
Article CAS PubMed Google Scholar
Vajaria BN, Patel PS. Glycosylation: a hallmark of cancer? Glycoconj J. 2017;34:147–56.
Article CAS PubMed Google Scholar
Mereiter S, Balmana M, Campos D, Gomes J, Reis CA. Glycosylation in the era of cancer-targeted therapy: where are we heading? Cancer Cell. 2019;36:6–16.
Article CAS PubMed Google Scholar
In: Varki A, Cummings RD, Esko JD, Stanley P, Hart GW, Aebi M et al. editors. Essentials of Glycobiology, 4th edn. New York: Cold Spring Harbor; 2022.
Comunale MA, Lowman M, Long RE, Krakover J, Philip R, Seeholzer S, et al. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res. 2006;5:308–15.
Article CAS PubMed Google Scholar
Goldman R, Ressom HW, Varghese RS, Goldman L, Bascug G, Loffredo CA, et al. Detection of hepatocellular carcinoma using glycomic analysis. Clin Cancer Res. 2009;15:1808–13.
Article CAS PubMed PubMed Central Google Scholar
Mehta A, Norton P, Liang H, Comunale MA, Wang M, Rodemich-Betesh L, et al. Increased levels of tetra-antennary N-linked glycan but not core fucosylation are associated with hepatocellular carcinoma tissue. Cancer Epidemiol Biomark Prev. 2012;21:925–33.
Mehta A, Herrera H, Block T. Glycosylation and liver cancer. Adv Cancer Res. 2015;126:257–79.
Article CAS PubMed PubMed Central Google Scholar
In: Varki A, Cummings RD, Esko JD, Stanley P, Hart GW, Aebi M et al. editors. Essentials of Glycobiology, 3rd edn. New York: Cold Spring Harbor; 2015.
Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA, Tabak LA. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology. 2012;22:736–56.
Article CAS PubMed Google Scholar
Brockhausen I, Stanley P O-GalNAc Glycans. In: Varki A, Cummings RD, Esko JD, Stanley P, Hart GW, Aebi M et al. editors. Essentials of Glycobiology, 3rd edn. New York: Cold Spring Harbor; 2015, pp 113–23.
Zachara N, Akimoto Y, Hart GW The O-GlcNAc Modification. In: Varki A, Cummings RD, Esko JD, Stanley P, Hart GW, Aebi M et al. editors. Essentials of Glycobiology, 3rd edn. New York: Cold Spring Harbor; 2015, pp 239–51.
Zeidan Q, Hart GW. The intersections between O-GlcNAcylation and phosphorylation: implications for multiple signaling pathways. J Cell Sci. 2010;123:13–22.
Article CAS PubMed Google Scholar
Schwarz F, Aebi M. Mechanisms and principles of N-linked protein glycosylation. Curr Opin Struct Biol. 2011;21:576–82.
Article CAS PubMed Google Scholar
Harduin-Lepers A, Vallejo-Ruiz V, Krzewinski-Recchi MA, Samyn-Petit B, Julien S, Delannoy P. The human sialyltransferase family. Biochimie. 2001;83:727–37.
Article CAS PubMed Google Scholar
Miyoshi E, Moriwaki K, Nakagawa T. Biological function of fucosylation in cancer biology. J Biochem. 2008;143:725–9.
Article CAS PubMed Google Scholar
Li J, Hsu HC, Mountz JD, Allen JG. Unmasking fucosylation: from cell adhesion to immune system regulation and diseases. Cell Chem Biol. 2018;25:499–512.
Shan M, Yang D, Dou H, Zhang L. Fucosylation in cancer biology and its clinical applications. Prog Mol Biol Transl Sci. 2019;162:93–119.
Article CAS PubMed Google Scholar
Blomme B, Van Steenkiste C, Callewaert N, Van Vlierberghe H. Alteration of protein glycosylation in liver diseases. J Hepatol. 2009;50:592–603.
Article CAS PubMed Google Scholar
Nguyen AT, Chia J, Ros M, Hui KM, Saltel F, Bard F. Organelle specific O-glycosylation drives MMP14 activation, tumor growth, and metastasis. Cancer Cell. 2017;32:639–53.
Article CAS PubMed Google Scholar
Wu Q, Liu HO, Liu YD, Liu WS, Pan D, Zhang WJ, et al. Decreased expression of hepatocyte nuclear factor 4alpha (Hnf4alpha)/microRNA-122 (miR-122) axis in hepatitis B virus-associated hepatocellular carcinoma enhances potential oncogenic GALNT10 protein activity. J Biol Chem. 2015;290:1170–85.
Article CAS PubMed Google Scholar
Wu YM, Liu CH, Hu RH, Huang MJ, Lee JJ, Chen CH, et al. Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor. Cancer Res. 2011;71:7270–9.
Article CAS PubMed Google Scholar
Liu Y, Liu H, Yang L, Wu Q, Liu W, Fu Q, et al. Loss of N-Acetylgalactosaminyltransferase-4 orchestrates oncogenic MicroRNA-9 in hepatocellular carcinoma. J Biol Chem. 2017;292:3186–3200.
Article CAS PubMed PubMed Central Google Scholar
Huang MJ, Hu RH, Chou CH, Hsu CL, Liu YW, Huang J, et al. Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling. Oncotarget. 2015;6:5650–65.
Article PubMed PubMed Central Google Scholar
Wu YM, Liu CH, Huang MJ, Lai HS, Lee PH, Hu RH, et al. C1GALT1 enhances proliferation of hepatocellular carcinoma cells via modulating MET glycosylation and dimerization. Cancer Res. 2013;73:5580–90.
Article CAS PubMed Google Scholar
Liu CH, Hu RH, Huang MJ, Lai IR, Chen CH, Lai HS, et al. C1GALT1 promotes invasive phenotypes of hepatocellular carcinoma cells by modulating integrin beta1 glycosylation and activity. PLoS One. 2014;9:e94995.
Article PubMed PubMed Central Google Scholar
Zhu Q, Zhou L, Yang Z, Lai M, Xie H, Wu L, et al. O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation. Med Oncol. 2012;29:985–93.
Article CAS PubMed Google Scholar
Yang Y, Yan Y, Yin J, Tang N, Wang K, Huang L, et al. O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N(6)-methyladenosine-dependent manner. Signal Transduct Target Ther. 2023;8:63.
Article CAS PubMed PubMed Central Google Scholar
Chu Y, Jiang M, Wu N, Xu B, Li W, Liu H, et al. O-GlcNAcylation of SIX1 enhances its stability and promotes Hepatocellular Carcinoma Proliferation. Theranostics. 2020;10:9830–42.
Article CAS PubMed PubMed Central Google Scholar
Zhou P, Chang WY, Gong DA, Huang LY, Liu R, Liu Y, et al. O-GlcNAcylation of SPOP promotes carcinogenesis in hepatocellular carcinoma. Oncogene. 2023;42:725–736.
Article CAS PubMed Google Scholar
Jiang T, Yang J, Yang H, Chen W, Ji K, Xu Y, et al. SLC35B4 stabilizes c-MYC protein by O-GlcNAcylation in HCC. Front Pharm. 2022;13:851089.
Wu W, Zheng X, Wang J, Yang T, Dai W, Song S, et al. O-GlcNAcylation on Rab3A attenuates its effects on mitochondrial oxidative phosphorylation and metastasis in hepatocellular carcinoma. Cell Death Dis. 2018;9:970.
Article PubMed PubMed Central Google Scholar
Cao B, Duan M, Xing Y, Liu C, Yang F, Li Y, et al. O-GlcNAc transferase activates stem-like cell potential in hepatocarcinoma through O-GlcNAcylation of eukaryotic initiation factor 4E. J Cell Mol Med. 2019;23:2384–98.
Article CAS PubMed PubMed Central Google Scholar
Buren S, Gomes AL, Teijeiro A, Fawal MA, Yilmaz M, Tummala KS, et al. Regulation of OGT by URI in response to glucose confers c-MYC-dependent survival mechanisms. Cancer Cell. 2016;30:290–307.
Article CAS PubMed Google Scholar
Zhang X, Qiao Y, Wu Q, Chen Y, Zou S, Liu X, et al. The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis. Nat Commun. 2017;8:15280.
Article CAS PubMed PubMed Central Google Scholar
Gao S, Miao Y, Liu Y, Liu X, Fan X, Lin Y, et al. Reciprocal regulation between O-GlcNAcylation and beta-Catenin facilitates cell viability and inhibits apoptosis in liver cancer. DNA Cell Biol. 2019;38:286–96.
Article CAS PubMed Google Scholar
Takayama H, Ohta M, Iwashita Y, Uchida H, Shitomi Y, Yada K, et al. Altered glycosylation associated with dedifferentiation of hepatocellular carcinoma: a lectin microarray-based study. BMC Cancer. 2020;20:192.
留言 (0)